We took advantage of the multimeric structure and extraordinary antigen sensitivity of natural T cell receptors (TCRs) to engineer bispecific chimeric TCRs that may be more effective at treating cancer than traditional chimeric antigen receptor T cells. The dual-targeting approach helps to prevent relapses by addressing the variability among cancer cells in antigen expression.
Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Learn more
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: CD19–CD22 Bi-ChTCR T cells eradicate heterogeneous tumors in vivo.
References
Abramson, J. S. et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143, 404–416 (2024). This paper presents clinical responses to CD19 CAR T cell therapy (lisocabtagene maraleucel) in patients with relapsed or refractory B cell lymphoma.
CASPubMedGoogle Scholar
Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27, 1419–1431 (2021). This paper describes lower levels or complete absence of CD19 antigen at relapse in patients treated with CD19 CAR T cells.
CASPubMedPubMed CentralGoogle Scholar
Salter, A. I. et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci. Signal. 14, eabe2606 (2021). This paper compares the phosphorylation of key signaling partners after TCR and CAR engagement, showing that LAT is poorly activated in CAR T cells.
CASPubMedPubMed CentralGoogle Scholar
Minguet, S., Maus, M. V. & Schamel, W. W. From TCR fundamental research to innovative chimeric antigen receptor design. Nat. Rev. Immunol.https://doi.org/10.1038/s41577-024-01093-7 (2024). This review article presents the various CAR and chimeric TCR designs described thus far.
ArticlePubMedGoogle Scholar
Download references
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Simon, S. et al. Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy. Nat. Cancer https://doi.org/10.1038/s43018-025-00927-0 (2025).
Rights and permissions
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Bispecific chimeric T cell receptors tackle tumor heterogeneity. Nat Cancer (2025). https://doi.org/10.1038/s43018-025-00936-z
Download citation
Published:31 March 2025
DOI:https://doi.org/10.1038/s43018-025-00936-z
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative